[HTML][HTML] Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection
D Yuan, M Li, Y Zhou, L Shi, J Lu, G Fu… - Journal of Virus Eradication, 2023 - Elsevier
Antiretroviral therapy (ART) aims to inhibit HIV replication, decrease CD4 T cell loss, and
immune function recovery in order to reduce the morbidity and mortality associated with the …
immune function recovery in order to reduce the morbidity and mortality associated with the …
[HTML][HTML] Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
S Khemla, A Meesing, W Sribenjalux… - Drug Target …, 2023 - ncbi.nlm.nih.gov
Methods: We conducted a prospective, open-label, cohort study in people with HIV aged≥
18 years who had undergone at least 6 months of EFV-based therapy, had HIV-1 ribonucleic …
18 years who had undergone at least 6 months of EFV-based therapy, had HIV-1 ribonucleic …
[HTML][HTML] Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES …
Objectives The aim of this study was to assess the efficacy of dolutegravir plus lamivudine
(DTG+ 3TC) in a large set of virologically suppressed HIV-1 infected individuals with or …
(DTG+ 3TC) in a large set of virologically suppressed HIV-1 infected individuals with or …
[HTML][HTML] Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and …
Real-world experience with low-level viraemia (LLV) and its impact remain less reported
among people living with HIV (PLWH) who receive antiretroviral therapy (ART) containing …
among people living with HIV (PLWH) who receive antiretroviral therapy (ART) containing …
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor …
H Álvarez, A Mocroft, L Ryom… - Clinical Infectious …, 2023 - academic.oup.com
Background There are conflicting data regarding baseline determinants of virological
nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting …
nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting …
Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study
PGA Oomen, S Dijkstra, LM Hofstra… - Journal of Medical …, 2023 - Wiley Online Library
The etiology of viral blips is not yet fully elucidated. One of the hypotheses is that blips reflect
variations in residual viremia (RV) near the detectability threshold. In this study, we …
variations in residual viremia (RV) near the detectability threshold. In this study, we …
Plasma HIV-1 RNA and CD4⁺ T-cell counts are determinants of virological non-suppression outcomes with initial integrase inhibitor-based regimens: A prospective …
H Álvarez, A Mocroft, L Ryom… - Clinical Infectious …, 2023 - discovery.ucl.ac.uk
BACKGROUND: There are conflicting data regarding baseline determinants of virological
non-suppression outcomes in persons with HIV who initiate antiretroviral treatment (ART) …
non-suppression outcomes in persons with HIV who initiate antiretroviral treatment (ART) …
Humoral Response after Two Doses of BNT162b2 mRNA vaccine has a role in predicting response after three doses that is related to plasma HIV viremia and nadir …
M Basso, N Pirola, S Pascoli, B Bragato, A Vinci… - Vaccines, 2022 - mdpi.com
We investigated the spike IgG levels of HIV+ patients on antiretroviral therapy six months
after they received their second dose (T2) and six months after the third dose (T3) of the …
after they received their second dose (T2) and six months after the third dose (T3) of the …
Predicting factors of plasma HIV RNA undetectability after switching to co-formulated bictegravir, emtricitabine, and tenofovir alafenamide in experienced HIV-1 …
M Basso, G Battagin, S Nicolè, MC Rossi, F Colombo… - Viruses, 2023 - mdpi.com
Switching to bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) from other
antiretroviral regimens is safe and effective for virologically suppressed people living with …
antiretroviral regimens is safe and effective for virologically suppressed people living with …
[HTML][HTML] Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy
JY Hsu, HY Sun, TW Hsieh, SY Chang… - Journal of Global …, 2022 - Elsevier
Objectives We aimed to investigate the incidence of low-level viremia (LLV) and its impact
on virologic failure (VF) in people living with HIV (PLWH) on stable antiretroviral therapy …
on virologic failure (VF) in people living with HIV (PLWH) on stable antiretroviral therapy …